Please assess the completion status of the following clinical trial:

Trial Title: Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged more than 18 years.~* Refractory or relapsed peripheral T-cell NHL (PTCL)~* Cutaneous T cell lymphoma (CTCL) in relapse or refractory to topical therapy~* ECOG score less than 2~* No major organ dysfunction unrelated to lymphoma.~Exclusion Criteria:~* Pregnant or breast feeding women~* ECOG score \> 2~* Estimate survival time \< 3 months~* Active infection or severe organ dysfunction or psychiatric condition that unable patients to receive chemotherapy~* Creatinine clearance \< 10 ml/min or severe hepatic dysfunction not related to lymphoma.~* Previous chemotherapy/immunotherapy within 3 weeks before study entry~* Known seropositive for or active viral infection HIV, EBV, HCV~* CNS lymphoma~* T-cell Leukemia lymphoma associated with HTLV1~* Sezary syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bendamustine (Type: EXPERIMENTAL): Bendamustine at the dose of 120 mg/m2 IV over 60 minutes on days 1 and 2 every 21 days for 6 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).